SAB Biotherapeutics, Inc. – NASDAQ:SABS

SAB Biotherapeutics stock price today

$2.02
-2.15
-51.67%
Financial Health
0
1
2
3
4
5
6
7
8
9

SAB Biotherapeutics stock price monthly change

+39.80%
month

SAB Biotherapeutics stock price quarterly change

+39.80%
quarter

SAB Biotherapeutics stock price yearly change

+505.80%
year

SAB Biotherapeutics key metrics

Market Cap
40.88M
Enterprise value
15.15M
P/E
-0.84
EV/Sales
0.18
EV/EBITDA
-0.61
Price/Sales
0.21
Price/Book
0.57
PEG ratio
N/A
EPS
-6.73
Revenue
2.60M
EBITDA
-37.11M
Income
-39.86M
Revenue Q/Q
62.54%
Revenue Y/Y
-58.89%
Profit margin
-33.5%
Oper. margin
-40.85%
Gross margin
7.69%
EBIT margin
-40.85%
EBITDA margin
-1426.22%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

SAB Biotherapeutics stock price history

SAB Biotherapeutics stock forecast

SAB Biotherapeutics financial statements

SAB Biotherapeutics, Inc. (NASDAQ:SABS): Profit margin
Jun 2023 85.51K -6.88M -8046.13%
Sep 2023 1.26M -5.10M -402.59%
Dec 2023 305.01K -22.85M -7493.75%
Mar 2024 944.57K -5.02M -532.06%
SAB Biotherapeutics, Inc. (NASDAQ:SABS): Analyst Estimates
Sep 2025 208.20K -6.51M -3131.36%
Oct 2025 208.20K -7.30M -3506.74%
Dec 2025 138.29K -62.88M -45472.9%
Dec 2025 138.29K -7.39M -5346.18%
  • Analysts Price target

  • Financials & Ratios estimates

SAB Biotherapeutics, Inc. (NASDAQ:SABS): Debt to assets
Jun 2023 35442560 15.72M 44.37%
Sep 2023 28336297 13.08M 46.16%
Dec 2023 83941253 26.64M 31.74%
Mar 2024 71371082 18.54M 25.99%
SAB Biotherapeutics, Inc. (NASDAQ:SABS): Cash Flow
Jun 2023 -4.89M -22.68K -363.78K
Sep 2023 -5.16M -40.85K -140.30K
Dec 2023 -13.44M -67.86K 67.63M
Mar 2024 -10.91M -31.35M -227.02K

SAB Biotherapeutics alternative data

SAB Biotherapeutics, Inc. (NASDAQ:SABS): Employee count
Aug 2023 56
Sep 2023 56
Oct 2023 56
Nov 2023 56
Dec 2023 56
Jan 2024 56
Feb 2024 56
Mar 2024 56
Apr 2024 56
May 2024 57
Jun 2024 57
Jul 2024 57

SAB Biotherapeutics other data

4.49% -5.02%
of SABS is owned by hedge funds
1.93M -2.16M
shares is hold by hedge funds

SAB Biotherapeutics, Inc. (NASDAQ:SABS): Insider trades (number of shares)
Period Buy Sel
Nov 2023 16000 0
Dec 2023 1740 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
SULLIVAN EDDIE JOE director, officer: Chief Execut..
Common Stock 1,740 $0.88 $1,531
Purchase
KING MICHAEL officer: CHIEF FINANCIAL OFFICER
Common Stock 5,000 $0.9 $4,500
Purchase
REICH SAMUEL J director, officer: Executive Ch..
Common Stock 11,000 $0.9 $9,845
Option
SESSA CAPITAL (MASTER), L.P. director
Common Stock 4,584,571 N/A N/A
Option
SESSA CAPITAL (MASTER), L.P. director
Series A-2 Convertible Preferred Stock 28,380 $0.63 $17,879
Option
SESSA CAPITAL (MASTER), L.P. director
Series A-1 Convertible Preferred Stock 31,269 $0.63 $19,699
Option
MOIN ANDREW director
Common Stock 4,584,571 N/A N/A
Option
MOIN ANDREW director
Series A-2 Convertible Preferred Stock 28,380 $0.63 $17,879
Option
MOIN ANDREW director
Series A-1 Convertible Preferred Stock 31,269 $0.63 $19,699
Option
ELLIAS HELEN K. director
Common Stock 2,857,142 N/A N/A
Wednesday, 6 November 2024
globenewswire.com
Thursday, 3 October 2024
accesswire.com
Monday, 30 September 2024
accesswire.com
Friday, 27 September 2024
accesswire.com
accesswire.com
accesswire.com
Tuesday, 24 September 2024
accesswire.com
Monday, 23 September 2024
accesswire.com
Friday, 20 September 2024
accesswire.com
Thursday, 19 September 2024
accesswire.com
Wednesday, 18 September 2024
accesswire.com
Tuesday, 17 September 2024
accesswire.com
accesswire.com
Friday, 13 September 2024
accesswire.com
globenewswire.com
Thursday, 12 September 2024
accesswire.com
accesswire.com
Tuesday, 10 September 2024
accesswire.com
Monday, 9 September 2024
accesswire.com
Friday, 6 September 2024
accesswire.com
Thursday, 5 September 2024
accesswire.com
Wednesday, 4 September 2024
globenewswire.com
Thursday, 8 August 2024
globenewswire.com
Monday, 5 August 2024
globenewswire.com
Thursday, 20 June 2024
globenewswire.com
Tuesday, 18 June 2024
globenewswire.com
Thursday, 30 May 2024
globenewswire.com
Tuesday, 21 May 2024
globenewswire.com
Monday, 20 May 2024
globenewswire.com
Monday, 6 May 2024
globenewswire.com
  • What's the price of SAB Biotherapeutics stock today?

    One share of SAB Biotherapeutics stock can currently be purchased for approximately $2.02.

  • When is SAB Biotherapeutics's next earnings date?

    Unfortunately, SAB Biotherapeutics's (SABS) next earnings date is currently unknown.

  • Does SAB Biotherapeutics pay dividends?

    No, SAB Biotherapeutics does not pay dividends.

  • How much money does SAB Biotherapeutics make?

    SAB Biotherapeutics has a market capitalization of 40.88M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 90.63% to 2.24M US dollars.

  • What is SAB Biotherapeutics's stock symbol?

    SAB Biotherapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SABS".

  • What is SAB Biotherapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of SAB Biotherapeutics?

    Shares of SAB Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does SAB Biotherapeutics have?

    As Jul 2024, SAB Biotherapeutics employs 57 workers, which is 2% more then previous quarter.

  • When SAB Biotherapeutics went public?

    SAB Biotherapeutics, Inc. is publicly traded company for more then 4 years since IPO on 9 Feb 2021.

  • What is SAB Biotherapeutics's official website?

    The official website for SAB Biotherapeutics is sabbiotherapeutics.com.

  • Where are SAB Biotherapeutics's headquarters?

    SAB Biotherapeutics is headquartered at 2100 East 54th Street North, Sioux Falls, SD.

  • How can i contact SAB Biotherapeutics?

    SAB Biotherapeutics's mailing address is 2100 East 54th Street North, Sioux Falls, SD and company can be reached via phone at +60 5 679 6980.

SAB Biotherapeutics company profile:

SAB Biotherapeutics, Inc.

sabbiotherapeutics.com
Exchange:

NASDAQ

Full time employees:

57

Industry:

Biotechnology

Sector:

Healthcare

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

2100 East 54th Street North
Sioux Falls, SD 57104

CIK: 0001833214
ISIN: US78397T2024
CUSIP: 78397T103